Wednesday, 18 Nov 2026 Breaking: Bangladesh: Former Bangladeshi MP Lt Col (Retd) Md Nazrul Islam Hiru arrested 
BREAKING: Apple launches AI platform | Tesla earnings beat estimates | Nvidia stock surges | Bitcoin crosses major resistance
Business

Sudarshan Pharma Eyes Global Growth with Proposed 9.5% Stake in US-Based MedTherapy Biotechnology

Sudarshan Pharma Eyes Global Growth with Proposed 9.5% Stake in US-Based MedTherapy Biotechnology

PNN
Mumbai (Maharashtra) [India], September 7: Sudarshan Pharma Industries Limited is looking to accelerate its global expansion and diversify into advanced oncology with a proposed acquisition of a 9.50% equity stake in US-based MedTherapy Biotechnology Inc.
The strategic investment, approved by the company’s Board, is expected to mark Sudarshan Pharma’s entry into the emerging cell and gene therapy ecosystem, particularly the CAR-T therapy segment. The move could broaden the company’s existing pharmaceutical and specialty-chemical business into higher-technology and innovation-led healthcare opportunities.
US-India platform at the centre of strategy
MedTherapy Biotechnology is developing an integrated CAR-T cell therapy and contract development and manufacturing platform, with technology development capabilities in the US and manufacturing infrastructure in India.
For Sudarshan Pharma, the proposed association could combine MedTherapy’s biotechnology capabilities with the company’s commercial reach, pharmaceutical relationships, sourcing expertise and execution capabilities. According to the company, the partnership has the potential to create a US-India platform covering innovation, manufacturing, commercialisation and patient access.
“This proposed investment represents a bold and potentially transformative step in Sudarshan Pharma’s growth journey,” said Hemal Mehta, Chairman and Managing Director, Sudarshan Pharma Industries Limited, adding that the company is seeking to enter an innovative area of modern healthcare while establishing a stronger presence in the United States.
Multiple growth avenues
The proposed investment could provide Sudarshan Pharma with access to the US biotechnology market and participation in advanced oncology. The company has identified potential opportunities across specialised technology, customers, contracts and distribution, as well as development, manufacturing, licensing and commercialisation.
https://www.bseindia.com/xml-data/corpfiling/AttachLive/6a47a13c-6520-43c4-b371-9852bf1ddb50.pdf
A key strategic element is the possibility of combining **US-based innovation with cost-efficient Indian manufacturing, creating a platform that could potentially scale across international markets.
The proposed transaction could also change the profile of Sudarshan Pharma by adding exposure to innovation-led healthcare segments characterised by specialised capabilities, significant unmet medical needs and international market potential.
Promoters also propose investment
Alongside the company’s proposed 9.50% investment, promoters Hemal Mehta and Sachin Mehta have separately proposed acquiring 1.50% each in MedTherapy Biotechnology. This would take the combined proposed interest of the company and its two promoters to 12.50%.
The transaction is expected to involve cash consideration denominated in US dollars. However, the proposed acquisition remains subject to legal, financial, commercial and technical due diligence, definitive agreements, applicable approvals and compliance with overseas-investment regulations.
Sudarshan Pharma is targeting completion by March 31, 2027, subject to fulfilment of the applicable conditions.
A potential shift towards innovation-led healthcare
Sachin Mehta, Joint Managing Director of Sudarshan Pharma, said the investment could provide the company with a platform spanning technology, manufacturing, market access and commercialisation, with the potential to build a scalable global business and create sustainable shareholder value.
The proposed deal represents a strategic shift in the company’s long-term growth narrative. While Sudarshan Pharma currently operates across contract manufacturing, chemical sourcing, pharmaceutical products and healthcare solutions the proposed MedTherapy investment could give it exposure to advanced biotechnology and global oncology markets.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same.)

Tags

Related News

India hopes to sign EU trade pact in December, says Commerce Secretary
Business
India hopes to sign EU trade pact in December, says Commerce Secretary

<p>New Delhi [India], November 18 (ANI): India hopes to sign its free trade agreement with the European Union in Decembe...

India seeks Italy's support for European ship recycling approvals, eyes EUR 50 billion bilateral trade: Piyush Goyal
Business
India seeks Italy's support for European ship recycling approvals, eyes EUR 50 billion bilateral trade: Piyush Goyal

<p>Rome [Italy], November 18 (ANI): India has sought Italy's support for securing European Commission approval for India...

India’s first commercial sustainable aviation fuel plant ready for production at IOC’s refinery: Chairman Sahney
Business
India’s first commercial sustainable aviation fuel plant ready for production at IOC’s refinery: Chairman Sahney

<p>New Delhi [India], November 18 (ANI): India’s first commercial-scale plant for manufacturing sustainable aviation fue...

India, Italy exploring faster certification, approval mechanisms to ease market access: Piyush Goyal
Business
India, Italy exploring faster certification, approval mechanisms to ease market access: Piyush Goyal

<p>Rome [Italy], November 18 (ANI): Union Commerce and Industry Minister Piyush Goyal on Wednesday said India and Italy...

PM Modi to inaugurate FICCI’s centenary year convention tomorrow
Business
PM Modi to inaugurate FICCI’s centenary year convention tomorrow

<p>New Delhi [India], November 18 (ANI): Prime Minister Narendra Modi will inaugurate and address FICCI’s Annual General...

Indian steelmakers rank among top 10 most competitive globally: Ashok Sahay
Business
Indian steelmakers rank among top 10 most competitive globally: Ashok Sahay

<p>New Delhi [India], November 18 (ANI): Indian steelmakers rank among the top 10 most competitive steel producers in th...